ProCE Banner Activity

Role of Quantitative HBsAg Testing in Clinical Practice for People With CHB

Podcast Episodes

Listen as Ira M. Jacobson, MD; Paul Y. Kwo, MD; and Tatyana Kushner, MD, MSCE, discuss the role of quantitative HBsAg testing in current clinical practice and where it may play a role in the future.

Released: November 29, 2023

Share

Faculty

Ira Jacobson

Ira Jacobson, MD

Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Tatyana Kushner

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Gastroenterology/ Hepatology
Department of Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Faculty Disclosure

Primary Author

Ira Jacobson, MD

Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Ira Jacobson, MD: researcher: Assembly Biosciences, Bristol-Myers Squibb, Eiger, Enanta, Genkyotex, Gilead, GlaxoSmithKline, Intercept, Janssen, Lilly, Merck, Mirum, Novo Nordisk; consultant/advisor: Aligos, Arbutus, Arrowhead, Galapagos, Gilead, GlaxoSmithKline, Intercept, Janssen, Merck, Roche, Takeda; data monitoring committee: Aligos, Altimmune, GlaxoSmithKline, Takeda.

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Gastroenterology/ Hepatology
Department of Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York

Tatyana Kushner, MD, MSCE: consultant/advisor/speaker: AbbVie, Aligos, GlaxoSmithKline; researcher: Gilead.

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD: consultant/advisor: Aligos, Drug Farm, Eiger, Galapagos, Gilead, HEPQuant, Inventiva, Mallinckrodt, Mirum, Surrozen; researcher: Altimmune, Eiger, Gilead, Novo Nordisk; individual publicly traded stocks/stock options: Durect.